Breast Cancer: Results of monarcHER found abemaciclib + trastuzumab +/- fulvestrant was associated w/numerically improved overall survival when compared to chemo + trastuzumab among pts w/HR+, HER2+ advanced breast cancer.
My name is Sarah Delany. I'm a breast medical oncologist at Dana Farber Cancer Institute. And at as mo this year we presented results of monarch er which was looking at the final overall survival analysis from this trial. This was a randomized Phase two study in patients with pre treated metastatic her two positive disease in which patients were randomized to receive Obama cyclops with trust is a mob with or without full restaurant. And it was compared to treatment of physicians choice therapy. And we had already seen that the Obama cycle containing arms are associated With improved progression free survival. But we now are seeing data regarding overall survival suggesting that the Obama cyclops containing regimens were associated with improved overall survival compared to treatment of physicians choice therapy with about 30 months of overall survival in the Obama cycle of arms compared to about 23 months in the treatment of physicians choice arm. There was also an exploratory analysis suggesting that the Luminal subtypes also had longer progression free survival and overall survival compared to non Luminal subtypes. So overall I think it suggests that a femicide, the Plus trust you with or without investment does lead to numerically improved overall survival compared to standard of care chemotherapy with trust
